Corcept strengthens its relacorilant hand

Corcept Therapeutics, which has already filed its glucocorticoid receptor antagonist relacorilant with the FDA for platinum-resistant ovarian cancer, strengthened its case on Thursday with final overall survival data from the supporting Rosella trial. The study found that relacorilant plus Abraxane decreased the risk of death by 35% versus Abraxane alone, with median OS of 16.0 and 11.9 months respectively. These numbers look similar to those in an interim OS analysis reported last year, but still sent Corcept’s stock up 15% on Thursday. The study previously hit on PFS, with a hazard ratio of 0.70; a filing followed in December, and an FDA decision is expected by 11 July. Still, the Rosella results weren’t as emphatic as those from a phase 2 trial, and there might be questions about the combination used; other possible treatment options in platinum-resistant ovarian cancer include doxorubicin, gemcitabine and topotecan. Corcept is testing an Abraxane and Avastin combo in the phase 2 Bella trial, which also has platinum-sensitive ovarian and endometrial cancer cohorts. And the group has ambitions in cervical, prostate and pancreatic cancers, where phase 2 trials are ongoing or planned. Corcept also has a next-gen project, nenocorilant.

Notable phase 2 & 3 trials of relacorilant

Notes: *investigator-sponsored trial; ADT=androgen-deprivation therapy; PDAC=pancreatic ductal adenocarcinoma. Source: OncologyPipeline & clinicaltrials.gov.